Analystreport

Kiniksa Pharmaceuticals Cl A (NASDAQ: KNSA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $29.00 price target on the stock.

Kiniksa Pharmaceuticals, Ltd. - Class A  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm Check Earnings Report